Landos Biopharma Inc (LABP) Stock: What Does the Chart Say Wednesday?

The market has been high on Landos Biopharma Inc (LABP) stock recently. LABP gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Landos Biopharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LABP!

See Full LABP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With LABP Stock Today?

Landos Biopharma Inc (LABP) stock is higher by 6.31% while the S&P 500 is lower by -0.74% as of 10:01 AM on Wednesday, Oct 25. LABP is higher by $0.23 from the previous closing price of $3.61 on volume of 3,708 shares. Over the past year the S&P 500 is higher by 11.03% while LABP is higher by 0.52%. LABP lost -$4.82 per share in the over the last 12 months.

More About Landos Biopharma Inc

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. Click Here to get the full Stock Report for Landos Biopharma Inc stock.